127 related articles for article (PubMed ID: 37824765)
1. SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE.
Tsoukalas N; Kiakou M; Tolia M; Galanopoulos M; Tsapakidis K; Arvanitou E; Charalambakis N; Tountziaris V; Nikolaou M; Christofyllakis C
Exp Oncol; 2023 Oct; 45(2):263-268. PubMed ID: 37824765
[TBL] [Abstract][Full Text] [Related]
2. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].
Wang J; Liu LT; Cui D; He L; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264
[No Abstract] [Full Text] [Related]
3. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
[TBL] [Abstract][Full Text] [Related]
4. The Role of BRAF V600E in Reducing AUS/FLUS Diagnosis in Thyroid Fine Needle Aspiration.
Yin L; Tang Y; Yu S; Wang C; Xiao M; Wang Y; Liu SJ; Gao L; Huang K; Jin L
Endocr Pathol; 2019 Dec; 30(4):312-317. PubMed ID: 31529211
[TBL] [Abstract][Full Text] [Related]
5. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
Qi W; Shi C; Zhang P; Feng L; Wang J; Chen D
Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
[TBL] [Abstract][Full Text] [Related]
6. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the expression levels of BRAF
Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
[TBL] [Abstract][Full Text] [Related]
8. Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.
Colombo C; Muzza M; Proverbio MC; Tosi D; Soranna D; Pesenti C; Rossi S; Cirello V; De Leo S; Fusco N; Miozzo M; Bulfamante G; Vicentini L; Ferrero S; Zambon A; Tabano S; Fugazzola L
Thyroid; 2019 Feb; 29(2):237-251. PubMed ID: 30501571
[TBL] [Abstract][Full Text] [Related]
9. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
10. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
11. [BRAF-STATUS OF PAPILLARY THYROID CARCINOMAS AND STRATEGY OF SURGICAL TREATMENT].
Tarashchenko YN; Kovalenko AE; Bolgov MY; Guda BB; Shelkovoy EA; Nekrasov KA; Mankovskaya S; Kashuba VI
Klin Khir; 2015 Jun; (6):49-54. PubMed ID: 26521469
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF
Zhang Y; Luo YK; Zhang Y; Zhang MB; Guang Y; Xie F; Jiang B; Tang J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug; 41(4):517-523. PubMed ID: 31484615
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
[TBL] [Abstract][Full Text] [Related]
14. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
[TBL] [Abstract][Full Text] [Related]
16. Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Mutation.
Perdas E; Stawski R; Nowak D; Zubrzycka M
Curr Drug Targets; 2018; 19(14):1721-1729. PubMed ID: 29484992
[TBL] [Abstract][Full Text] [Related]
17. Incidence of
Kure S; Ishino K; Kudo M; Wada R; Saito M; Nagaoka R; Sugitani I; Naito Z
J Int Med Res; 2019 Nov; 47(11):5560-5572. PubMed ID: 31533501
[TBL] [Abstract][Full Text] [Related]
18. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
19. Circulating Tumor DNA Harboring the
Sato A; Tanabe M; Tsuboi Y; Niwa T; Shinozaki-Ushiku A; Seto Y; Murakami Y
Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
[No Abstract] [Full Text] [Related]
20. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
Straccia P; Brunelli C; Rossi ED; Lanza P; Martini M; Musarra T; Lombardi CP; Pontecorvi A; Fadda G
Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]